BCI
KYMR icon

Brinker Capital Investments’s Kymera Therapeutics KYMR Stock Holding History

Brinker Capital Investments’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$347K Buy
3,022
+40
+1% +$3.44K ﹤0.01% 1586
2026
Q1 		$248K Buy
2,982
+114
+4% +$9.03K ﹤0.01% 1749
2025
Q4 		$223K Buy
+2,868
New +$194K ﹤0.01% 1963

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Brinker Capital Investments's KYMR Position: Q2 2026 in Review

Brinker Capital Investments increased its Kymera Therapeutics (KYMR) stake by 1.3% in Q2 2026, buying an estimated $3.44K and bringing the position to 3,022 shares worth $347K. The position accounts for ﹤0.01% of the portfolio, ranked #1586.

Brinker Capital Investments first reported a position in KYMR in Q4 2025 and has held it in 3 quarters since. 276 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

  • Brinker Capital Investments held 3,022 shares of Kymera Therapeutics worth $347K as of Q2 2026.
  • Brinker Capital Investments bought 40 Kymera Therapeutics shares in Q2 2026, an estimated $3.44K.
  • Kymera Therapeutics made up ﹤0.01% of Brinker Capital Investments's portfolio in Q2 2026, its #1586 holding.
  • Brinker Capital Investments first reported a position in Kymera Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 276 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on Brinker Capital Investments's 13F filing for Q2 2026, filed 14 Aug 2026.